Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-160X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada ; day:30 ; month:5 ; year:2017 ; pages:1-13
Rheumatology international ; (30.5.2017), 1-13
- Schlagwort
-
Orthopädie
- Urheber
-
Weijers, Laure
- Beteiligte Personen und Organisationen
-
Baerwald, Christoph
Mennini, Francesco S.
Rodríguez-Heredia, José M.
Bergman, Martin J.
Choquette, Denis
Herrmann, Kirsten H.
Attinà, Giulia
Nappi, Carmela
Merino, Silvia Jimenez
Patel, Chad
Mtibaa, Mondher
Foo, Jason
SpringerLink (Online service)
- DOI
-
10.1007/s00296-017-3739-9
- URN
-
urn:nbn:de:1111-201706237302
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Weijers, Laure
- Baerwald, Christoph
- Mennini, Francesco S.
- Rodríguez-Heredia, José M.
- Bergman, Martin J.
- Choquette, Denis
- Herrmann, Kirsten H.
- Attinà, Giulia
- Nappi, Carmela
- Merino, Silvia Jimenez
- Patel, Chad
- Mtibaa, Mondher
- Foo, Jason
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis